| Literature DB >> 20936121 |
Cheng-Chia Yu1, Wen-Liang Lo, Yi-Wei Chen, Pin-I Huang, Han-Shui Hsu, Ling-Ming Tseng, Shih-Chieh Hung, Shou-Yen Kao, Charn-Jung Chang, Shih Hwa Chiou.
Abstract
Recent studies suggest that ALDH1 is a putative marker for HNSCC-derived cancer stem cells. However, the regulation mechanisms that maintain the stemness and metastatic capability of HNSCC-ALDH1(+) cells remain unclear. Initially, HNSCC-ALDH1(+) cells from HNSCC patient showed cancer stemness properties, and high expression of Bmi1 and Snail. Functionally, tumorigenic properties of HNSCC-ALDH1(+) cells could be downregulated by knockdown of Bmi-1. Overexpression of Bmi-1 altered in expression property ALDH1(-) cells to that of ALDH1(+) cells. Furthermore, knockdown of Bmi-1 enhanced the radiosensitivity of radiation-treated HNSCC-ALDH1(+) cells. Moreover, overexpression of Bmi-1 in HNSCC-ALDH1(-) cells increased tumor volume and number of pulmonary metastatic lesions by xenotransplant assay. Importantly, knock-down of Bmi1 in HNSCC-ALDH1(+) cells significantly decreased distant metastases in the lungs. Clinically, coexpression of Bmi-1/Snail/ALDH1 predicted the worst prognosis in HNSCC patients. Collectively, our data suggested that Bmi-1 plays a key role in regulating Snail expression and cancer stemness properties of HNSCC-ALDH1(+) cells.Entities:
Year: 2010 PMID: 20936121 PMCID: PMC2948925 DOI: 10.1155/2011/609259
Source DB: PubMed Journal: J Oncol ISSN: 1687-8450 Impact factor: 4.375
Case description, tumorigenic characteristics and treatment effects of ALDH1+ and ALDH1− HNSCC.
| Number of cells injected | ||||||||
|---|---|---|---|---|---|---|---|---|
| Case | Age/Sex | ALDH+ (%) | Spheres | Parental | ALDH1+ | ALDH1+ (Sh-Bmi 1) | ALDH1− | ALDH1− (Bmi 1Over) |
| Formation | ||||||||
| 1 | 71/ M | 44.2 | Yes | 1,000 (0/3) | 1,000 (1/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (1/3) |
| 3,000 (0/3) | 3,000 (3/3) | 3,000 (0/3) | 3,000 (0/3) | 3,000 (1/3) | ||||
| 10,000 (1/3) | 10,000 (3/3) | 10,000 (2/3) | 10,000 (1/3) | 10,000 (2/3) | ||||
|
| ||||||||
| 2 | 73/ F | 24.7 | Yes | 1,000 (0/3) | 1,000 (1/3) | 1,000 (1/3) | 1,000 (0/3) | 1,000 (0/3) |
| 3,000 (0/3) | 3,000 (2/3) | 3,000 (2/3) | 3,000 (0/3) | 3,000 (1/3) | ||||
| 10,000 (2/3) | 10,000 (2/3) | 10,000 (2/3) | 10,000 (0/3) | 10,000 (2/3) | ||||
|
| ||||||||
| 3 | 61 / F | 8.6 | Yes | 1,000 (0/3) | 1,000 (1/3) | 1,000 (1/3) | 1,000 (0/3) | 1,000 (0/3) |
| 3,000 (0/3) | 3,000 (3/3) | 3,000 (1/3) | 3,000 (0/3) | 3,000 (2/3) | ||||
| 10,000 (0/3) | 10,000 (3/3) | 10,000 (2/3) | 10,000 (0/3) | 10,000 (3/3) | ||||
|
| ||||||||
| 4 | 71 / M | 1.2 | Yes | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) |
| 3,000 (0/3) | 3,000 (3/3) | 3,000 (0/3) | 3,000 (0/3) | 3,000 (2/3) | ||||
| 10,000 (0/3) | 10,000 (3/3) | 10,000 (2/3) | 10,000 (0/3) | 10,000 (3/3) | ||||
|
| ||||||||
| 5 | 69 / M | 19.2 | Yes | 1,000 (0/3) | 1,000 (1/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) |
| 3,000 (0/3) | 3,000 (3/3) | 3,000 (1/3) | 3,000 (0/3) | 3,000 (2/3) | ||||
| 10,000 (1/3) | 10,000 (3/3) | 10,000 (2/3) | 10,000 (0/3) | 10,000 (3/3) | ||||
|
| ||||||||
| 6 | 72 / M | 5.5 | Yes | 1,000 (0/3) | 1,000 (1/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) |
| 3,000 (0/3) | 3,000 (3/3) | 3,000 (1/3) | 3,000 (0/3) | 3,000 (2/3) | ||||
| 10,000 (0/3) | 10,000 (3/3) | 10,000 (1/3) | 10,000 (0/3) | 10,000 (2/3) | ||||
ALDH1+: ALDH1-positive HNSCC cells; ALDH1−: ALDH1-negative HNSCC cells.
ALDH1+ or ALDH1+cells were injected into neck of SCID mice.
The sequences for the primers of quantitative RT-PCR.
| Gene(Accession No.) | Primer Sequence (5′ to 3′) | Product size (bp) | Tm (°C) |
|---|---|---|---|
| Oct-4(NM_002701) | F: GTGGAGAGCAACTCCGATG | 86 | 60 |
| R: TGCTCCAGCTTCTCCTTCTC | |||
|
| |||
| Nanog(NM_024865) | F: ATTCAGGACAGCCCTGATTCTTC | 76 | 60 |
| R: TTTTTGCGACACTCTTCTCTGC | |||
|
| |||
| SOX-2(NM_003106) | F: CGAGTGGAAACTTTTGTCGGA | 74 | 60 |
| R: TGTGCAGCGCTCGCAG | |||
|
| |||
| Musashi(NM_002442) | F: TCCCTCGGCGAGCACA | 64 | 60 |
| R: GACAGCCCCCCCACAAA | |||
|
| |||
| c-Myc(NM_002467) | F: GGAACGAGCTAAAACGGAGCT | 71 | 55 |
| R: GGCCTTTTCATTGTTTTCCAACT | |||
|
| |||
|
| F: CCAGCCGACACCAAGAAG | 130 | 55 |
| R: CGAATCAATCCAACAGTAGCC | |||
|
| |||
| Bmi1(NM_ 005180) | F | 124 | 50 |
| R | |||
|
| |||
| Nestin(NM_006617) | F: AGGAGGAGTTGGGTTCTG | 112 | 50 |
| R: GGAGTGGAGTCTGGAAGG | |||
|
| |||
| Snail(NM_005985) | F:GCTGCCAATGCTCATCTGGGACTCT | 300 | 55 |
| R: TTGAAGGGCTTTCGAGCCTGGAGAT | |||
|
| |||
| Slug(NM_003068) | F: GTGATTATTTCCCCGTATCTCTAT | 292 | 50 |
| R: CAATGGCATGGGGGTCTGAAAG | |||
|
| |||
| MDR-1 (NM_000927) | F: TGGCAAAGAAATAAAGCGACTGA | 76 | 60 |
| R: CAGGATGGGCTCCTGGG | |||
|
| |||
| MRP-1(X60111) | F: GCTTCCTCTTGGTGATATTCG | 176 | 50 |
| R: GCAGTTCAACGCATAGTGG | |||
|
| |||
| ABCG2(NM_004827) | F: CATGTACTGGCGAAGAATATTTGGT | 74 | 60 |
| R: CACGTGATTCTTCCACAAGCC | |||
|
| |||
| GAPDH(NM_002046) | F: CATCATCCCTGCCTCTACTG | 180 | 60 |
| R: GCCTGCTTCACCACCTTC | |||
Figure 1Isolation and Characterization of HNSCC-derived ALDH1-positive Cells. (a) Analyzing and sorting ALDH1+-positive and ALDH1−-negative from HNSCC tissues via FACScan. DEAB, an inhibitor of ALDH1, was used for negative control. (b) Evaluation of sphere body formation in the parental cells, ALDH1− cells, and ALDH1+cells. Sphere bodies were counted after 1 week. The numbers of resultant colonies (c) and invasion cells (d) from parental cells, ALDH1+ cells, and ALDH1−cells were counted in vitro. (e) Macroscopic features of cells in a nude mouse at 6 weeks after xenotransplantation. Blue arrow indicates the site of injection of ALDH1−cells. Red arrow indicates the site of injection of ALDH1+cells. Yellow arrow indicates the site of injection of ALDH1+cells. *P < .05. Data shown here are the mean ± SD of three experiments.
Figure 2Overexpression of Bmi-1 in HNSCC-ALDH1− cells or knockdown of Bmi-1 in HNSCC-ALDH+ cells modulates Snail expression and tumorigenicity in vitro. (a) Down-regulation of Bmi-1 mediated by lentiviral shRNA and expression of Snail and ALDH1 in HNSCC-ALDH1+ cells was analyzed by western blot. Colony formation (b) and migration/invasion ability (c) of shLuc.-expressing and shBmi-1-expressing HNSCC-ALDH1+cells was determined. (d) Total protein was prepared from control GFP–expressing andBmi-1-overexpressing HNSCC-ALDH1− cells and analyzed by immunoblotting with anti-Bmi-1, anti-Snail, anti-ALDH1, or anti-GAPDH antibodies as indicated. The amount of GAPDH protein from each crude cell extract was used as loading control. Colony formation (e) and migration/invasion ability (f) of Bmi-1-overexpressing and control-GFP-expressing HNSCC-ALDH1− were analyzed. *P < .05. Data shown here are the mean ± SD of three experiments.
Figure 3Stemness properties were enhanced in HNSCC-ALDH1− cells when Bmi-1 was overexpressed. (a) Gene expression microarray analysis (Gene tree) for altered genes differentially expressed in Bmi-1-overexpressing HNSCC-ALDH1− cells compared to HNSCC-ALDH1− cells by a hierarchy heat map. The time dependent changes of altered genes are presented on a log scale of expression values provided by GeneSpring GX software. (b) Principle component analysis (PCA) demonstrated that overexpression of Bmi-1 in HNSCC-ALDH1− cells could enhance the gene signature of embryonic stem cells (ESCs) in HNSCC-ALDH1− cells. (c) Multidimensional scaling analysis. Average lineage transcriptome distances between HNSCC-ALDH1+, HNSCC-ALDH1−, HNSCC-ALDH1+/sh-Bmi-1, and HNSCC-ALDH1−/Bmi1over cells. *P < .05. (d) Transcripts of Oct-4, Nanog, Sox2, KLF4, Lin28, Snail, Slug, MDR-1, and ABCG2 in HNSCC-ALDH1− and HNSCC-ALDH1−/Bmi-1over cells (*P < .05: ALDH1− versus Bmi-1-overexpressing ALDH1−).
The expression profiling of up-regulated genes in ALDH1−/Bmi1-overexpressed as compared to ALDH1− HNSCC.
| Probe set ID | Gene symbol | Gene title |
|---|---|---|
| 217757_at | A2M | alpha-2-macroglobulin |
| 209459_s_at | ABAT | 4-aminobutyrate aminotransferase |
| 213353_at | ABCA5 | ATP-binding cassette, sub-family A (ABC1), member 5 |
| 209993_at | ABCB1(MDR1) | ATP-binding cassette, sub-family B (MDR/TAP), member 1 |
| 214033_at | ABCC6 | ATP-binding cassette, sub-family C (CFTR/MRP), member 6 |
| 210246_s_at | ABCC8 | ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 204567_s_at | ABCG1 | ATP-binding cassette, sub-family G (WHITE), member 1 |
| 209735_at | ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 |
| 204151_x_at | AKR1C1 | aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase) |
| 209699_x_at | AKR1C2 | aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III) |
| 212224_at | ALDH1A1 | aldehyde dehydrogenase 1 family, member A1 |
| 204446_s_at | ALOX5 | arachidonate 5-lipoxygenase |
| 205216_s_at | APOH | apolipoprotein H (beta-2-glycoprotein I) |
| 39248_at | AQP3 | aquaporin 3 (Gill blood group) |
| 218501_at | ARHGEF3 | Rho guanine nucleotide exchange factor (GEF) 3 |
| 219087_at | ASPN | Aspirin |
| 201242_s_at | ATP1B1 | ATPase, Na+/K+ transporting, beta 1 polypeptide |
| 200921_s_at | BTG1 | B-cell translocation gene 1, anti-proliferative |
| 228067_at | C2orf55 | chromosome 2 open reading frame 55 |
| 206488_s_at | CD36 | CD36 molecule (thrombospondin receptor) |
| 208783_s_at | CD46 | CD46 molecule, complement regulatory protein |
| 1553970_s_at | CEL | carboxyl ester lipase (bile salt-stimulated lipase) |
| 203854_at | CFI | complement factor I |
| 205043_at | CFTR | cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) |
| 204260_at | CHGB | chromogranin B (secretogranin 1) |
| 221188_s_at | CIDEB | cell death-inducing DFFA-like effector b |
| 203953_s_at | CLDN3 | claudin 3 |
| 221042_s_at | CLMN | calmin (calponin-like, transmembrane) |
| 1567081_x_at | CLN6 | ceroid-lipofuscinosis, neuronal 6, late infantile, variant |
| 208791_at | CLU | Clusterin |
| 229831_at | CNTN3 | contactin 3 (plasmacytoma associated) |
| 205615_at | CPA1 | carboxypeptidase A1 (pancreatic) |
| 206212_at | CPA2 | carboxypeptidase A2 (pancreatic) |
| 205509_at | CPB1 | carboxypeptidase B1 (tissue) |
| 201117_s_at | CPE | carboxypeptidase E |
| 224829_at | CPEB4 | cytoplasmic polyadenylation element binding protein 4 |
| 204920_at | CPS1 | carbamoyl-phosphate synthetase 1, mitochondrial |
| 201990_s_at | CREBL2 | cAMP responsive element binding protein-like 2 |
| 205971_s_at | CTRB1 /// CTRB2 | chymotrypsinogen B1 /// chymotrypsinogen B2 |
| 214411_x_at | CTRB2 | chymotrypsinogen B2 |
| 209774_x_at | CXCL2 | chemokine (C-X-C motif) ligand 2 |
| 205765_at | CYP3A5 | cytochrome P450, family 3, subfamily A, polypeptide 5 |
| 228391_at | CYP4V2 | cytochrome P450, family 4, subfamily V, polypeptide 2 |
| 228739_at | CYS1 | cystin 1 |
| 222925_at | DCDC2 | doublecortin domain containing 2 |
| 205311_at | DDC | dopa decarboxylase (aromatic L-amino acid decarboxylase) |
| 210397_at | DEFB1 | defensin, beta 1 |
| 221081_s_at | DENND2D | DENN/MADD domain containing 2D |
| 214787_at | DENND4A | DENN/MADD domain containing 4A |
| 205684_s_at | DENND4C | DENN/MADD domain containing 4C |
| 214079_at | DHRS2 | dehydrogenase/reductase (SDR family) member 2 |
| 222850_s_at | DNAJB14 | DnaJ (Hsp40) homolog, subfamily B, member 14 |
| 225415_at | DTX3L | deltex 3-like (Drosophila) |
| 225645_at | EHF | Ets homologous factor |
| 210080_x_at | ELA3A | elastase 3A, pancreatic |
| 201510_at | ELF3 | E74-like factor 3 (ets domain transcription factor, epithelial-specific) |
| 206191_at | ENTPD3 | ectonucleoside triphosphate diphosphohydrolase 3 |
| 220012_at | ERO1LB | ERO1-like beta (S. cerevisiae) |
| 210103_s_at | FOXA2 | forkhead box A2 |
| 235201_at | FOXP2 | forkhead box P2 |
| 226847_at | FST | Follistatin |
| 205674_x_at | FXYD2 | FXYD domain containing ion transport regulator 2 |
| 205890_s_at | GABBR1 /// UBD | gamma-aminobutyric acid (GABA) B receptor, 1 /// ubiquitin D |
| 205848_at | GAS2 | growth arrest-specific 2 |
| 216733_s_at | GATM | glycine amidinotransferase (L-arginine:glycine amidinotransferase) |
| 204965_at | GC | group-specific component (vitamin D binding protein) |
| 219508_at | GCNT3 | glucosaminyl (N-acetyl) transferase 3, mucin type |
| 225853_at | GNPNAT1 | glucosamine-phosphate N-acetyltransferase 1 |
| 212950_at | GPR116 | G protein-coupled receptor 116 |
| 212070_at | GPR56 | G protein-coupled receptor 56 |
| 203924_at | GSTA1 | glutathione S-transferase A1 |
| 221942_s_at | GUCY1A3 | guanylate cyclase 1, soluble, alpha 3 |
| 228697_at | HINT3 | histidine triad nucleotide binding protein 3 |
| 209558_s_at | HIP1R | huntingtin interacting protein 1 related |
| 207062_at | IAPP | islet amyloid polypeptide |
| 213620_s_at | ICAM2 | intercellular adhesion molecule 2 |
| 203828_s_at | IL32 | interleukin 32 |
| 205945_at | IL6R | interleukin 6 receptor |
| 206598_at | INS | Insulin |
| 226535_at | ITGB6 | integrin, beta 6 |
| 226189_at | ITGB8 | integrin, beta 8 |
| 210078_s_at | KCNAB1 | potassium voltage-gated channel, shaker-related subfamily, beta member 1 |
| 219564_at | KCNJ16 | potassium inwardly-rectifying channel, subfamily J, member 16 |
| 205303_at | KCNJ8 | potassium inwardly-rectifying channel, subfamily J, member 8 |
| 212531_at | LCN2 | lipocalin 2 |
| 235970_at | LCORL | ligand dependent nuclear receptor corepressor-like |
| 1554006_a_at | LLGL2 | lethal giant larvae homolog 2 (Drosophila) |
| 225996_at | LONRF2 | LON peptidase N-terminal domain and ring finger 2 |
| 242931_at | LONRF3 | LON peptidase N-terminal domain and ring finger 3 |
| 226748_at | LYSMD2 | LysM, putative peptidoglycan-binding, domain containing 2 |
| 213975_s_at | LYZ | lysozyme (renal amyloidosis) |
| 222670_s_at | MAFB | v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) |
| 223577_x_at | MALAT1 | metastasis associated lung adenocarcinoma transcript 1 (non-protein coding) |
| 220945_x_at | MANSC1 | MANSC domain containing 1 |
| 204388_s_at | MAOA | monoamine oxidase A |
| 235077_at | MEG3 | maternally expressed 3 |
| 229254_at | MFSD4 | major facilitator superfamily domain containing 4 |
| 219797_at | MGAT4A | mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A |
| 204259_at | MMP7 | matrix metallopeptidase 7 (matrilysin, uterine) |
| 227747_at | MPZL3 | myelin protein zero-like 3 |
| 204438_at | MRC1 /// MRC1L1 | mannose receptor, C type 1 /// mannose receptor, C type 1-like 1 |
| 203037_s_at | MTSS1 | metastasis suppressor 1 |
| 212093_s_at | MTUS1 | mitochondrial tumor suppressor 1 |
| 213693_s_at | MUC1 | mucin 1, cell surface associated |
| 213375_s_at | N4BP2L1 | NEDD4 binding protein 2-like 1 |
| 220184_at | NANOG | Nanog homeobox |
| 209107_x_at | NCOA1 | nuclear receptor coactivator 1 |
| 1556057_s_at | NEUROD1 | neurogenic differentiation 1 |
| 206915_at | NKX2-2 | NK2 homeobox 2 |
| 225911_at | NPNT | Nephronectin |
| 205259_at | NR3C2 | nuclear receptor subfamily 3, group C, member 2 |
| 212768_s_at | OLFM4 | olfactomedin 4 |
| 203845_at | PCAF | p300/CBP-associated factor |
| 240317_at | PCDHB4 | protocadherin beta 4 |
| 212593_s_at | PDCD4 | programmed cell death 4 (neoplastic transformation inhibitor) |
| 213228_at | PDE8B | phosphodiesterase 8B |
| 225207_at | PDK4 | pyruvate dehydrogenase kinase, isozyme 4 |
| 205380_at | PDZK1 | PDZ domain containing 1 |
| 1553589_a_at | PDZK1IP1 | PDZK1 interacting protein 1 |
| 226459_at | PIK3AP1 | phosphoinositide-3-kinase adaptor protein 1 |
| 220954_s_at | PILRB | paired immunoglobulin-like type 2 receptor beta |
| 219584_at | PLA1A | phospholipase A1 member A |
| 206311_s_at | PLA2G1B | phospholipase A2, group IB (pancreas) |
| 221529_s_at | PLVAP | plasmalemma vesicle associated protein |
| 205912_at | PNLIP | pancreatic lipase |
| 211766_s_at | PNLIPRP2 | pancreatic lipase-related protein 2 |
| 208286_x_at | POU5F1(Oct4) | POU class 5 homeobox 1 /// POU class 5 homeobox 1B /// POU class 5 homeobox 1 pseudogene 3 /// POU class 5 homeobox 1 pseudogene 4 |
| 228469_at | PPID | Peptidylprolyl isomerase D (cyclophilin D) |
| 210670_at | PPY | pancreatic polypeptide |
| 242482_at | PRKAR1A | protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) |
| 227629_at | PRLR | Prolactin receptor |
| 228656_at | PROX1 | prospero homeobox 1 |
| 205869_at | PRSS1 | protease, serine, 1 (trypsin 1) |
| 205402_x_at | PRSS2 | protease, serine, 2 (trypsin 2) |
| 213421_x_at | PRSS3 | protease, serine, 3 |
| 203317_at | PSD4 | pleckstrin and Sec7 domain containing 4 |
| 203029_s_at | PTPRN2 | protein tyrosine phosphatase, receptor type, N polypeptide 2 |
| 219562_at | RAB26 | RAB26, member RAS oncogene family |
| 226436_at | RASSF4 | Ras association (RalGDS/AF-6) domain family member 4 |
| 223322_at | RASSF5 | Ras association (RalGDS/AF-6) domain family member 5 |
| 235638_at | RASSF6 | Ras association (RalGDS/AF-6) domain family member 6 |
| 204364_s_at | REEP1 | receptor accessory protein 1 |
| 209752_at | REG1A | regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread protein) |
| 205886_at | REG1B | regenerating islet-derived 1 beta (pancreatic stone protein, pancreatic thread protein) |
| 205815_at | REG3A | regenerating islet-derived 3 alpha |
| 1554003_at | RGNEF | Rho-guanine nucleotide exchange factor |
| 219263_at | RNF128 | ring finger protein 128 |
| 221614_s_at | RPH3AL | rabphilin 3A-like (without C2 domains) |
| 213939_s_at | RUFY3 | RUN and FYVE domain containing 3 |
| 210592_s_at | SAT1 | spermidine/spermine N1-acetyltransferase 1 |
| 203408_s_at | SATB1 | SATB homeobox 1 |
| 204035_at | SCG2 | secretogranin II (chromogranin C) |
| 205697_at | SCGN | secretagogin, EF-hand calcium binding protein |
| 229620_at | SEPP1 | Selenoprotein P, plasma, 1 |
| 202833_s_at | SERPINA1 | serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 |
| 202376_at | SERPINA3 | serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 |
| 209443_at | SERPINA5 | serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 |
| 213572_s_at | SERPINB1 | serpin peptidase inhibitor, clade B (ovalbumin), member 1 |
| 227627_at | SGK3 | serum/glucocorticoid regulated kinase family, member 3 |
| 219256_s_at | SH3TC1 | SH3 domain and tetratricopeptide repeats 1 |
| 204019_s_at | SH3YL1 | SH3 domain containing, Ysc84-like 1 (S. cerevisiae) |
| 213464_at | SHC2 | SHC (Src homology 2 domain containing) transforming protein 2 |
| 205799_s_at | SLC3A1 | solute carrier family 3 (cystine, dibasic and neutral amino acid transporters, activator of cystine, dibasic and neutral amino acid transport), member 1 |
| 223044_at | SLC40A1 | solute carrier family 40 (iron-regulated transporter), member 1 |
| 228221_at | SLC44A3 | solute carrier family 44, member 3 |
| 213139_at | SNAI2(Slug) | snail homolog 2 (Drosophila) |
| 1560228_at | SNAI3(Snail) | snail homolog 3 (Drosophila) |
| 213721_at | SOX2 | SRY (sex determining region Y)-box 2 |
| 200795_at | SPARCL1 | SPARC-like 1 (mast9, hevin) |
| 206239_s_at | SPINK1 | serine peptidase inhibitor, Kazal type 1 |
| 213921_at | SST | somatostatin |
| 216905_s_at | ST14 | suppression of tumorigenicity 14 (colon carcinoma) |
| 230285_at | SVIP | small VCP/p97-interacting protein |
| 227134_at | SYTL1 | synaptotagmin-like 1 |
| 202286_s_at | TACSTD2 | tumor-associated calcium signal transducer 2 |
| 205513_at | TCN1 | transcobalamin I (vitamin B12 binding protein, R binder family) |
| 203887_s_at | THBD | thrombomodulin |
| 209937_at | TM4SF4 | transmembrane 4 L six family member 4 |
| 226403_at | TMC4 | transmembrane channel-like 4 |
| 223503_at | TMEM163 | transmembrane protein 163 |
| 218345_at | TMEM176A | transmembrane protein 176A |
| 220532_s_at | TMEM176B | transmembrane protein 176B |
| 200847_s_at | TMEM66 | transmembrane protein 66 |
| 202687_s_at | TNFSF10 | tumor necrosis factor (ligand) superfamily, member 10 |
| 203824_at | TSPAN8 | tetraspanin 8 |
| 229169_at | TTC18 | tetratricopeptide repeat domain 18 |
| 209660_at | TTR | transthyretin (prealbumin, amyloidosis type I) |
| 231008_at | UNC5CL | Unc-5 homolog C (C. elegans)-like |
| 226344_at | ZMAT1 | zinc finger, matrin type 1 |
| 206059_at | ZNF91 | zinc finger protein 91 |
Figure 4Determination of the role of Bmi-1 on in vivo tumor growth and radioresistance in HNSCC-ALDH1+cells. (a) Tumor volume was measured after injection of either HNSCC-ALDH1+, sh-Bmi-1 treated HNSCC-ALDH1+, HNSCC-ALDH1, or Bmi-1-overexpressing HNSCC- ALDH1 cells into the neck of SCID mice. Error bars correspond to SD. (b) To determine the radiation effect on the cell survival rate, an ionizing radiation (IR) dose from 0 to 10Gy was used to treated with ALDH1+/vector, ALDH1+/sh-Bmi-1, ALDH1 /vector, or Bmi-1-overexpressing HNSCC- ALDH1 HNSCC cells.
Figure 5Elimination of metastatic activity in HNSCC-ALDH1+cells treated with shBmi-1. (a) Summary of the in vivo metastasis ability of different numbers of HNSCC-ALDH1+, sh-Bmi-1 treated HNSCC-ALDH1+, HNSCC- ALDH1, or Bmi-1-overexpressing HNSCC- ALDH1 cells examined by xenotransplantation analysis. (b) The average numbers of metastatic foci (left panel) and total weight (right panel) in the lungs of mice treated with either HNSCC-ALDH1+, sh-Bmi-1 treated HNSCC-ALDH1+, HNSCC- ALDH1, or Bmi-1-overexpressing HNSCC-ALDH1cells are shown. (*P < .05: ALDH1− versus Bmi-1-overexpressing ALDH1−; # P < .05: ALDH1+ versus shBmi-1 treated HNSCC-ALDH1+).
Figure 6Coexpression of Bmi-1, Snail, and ALDH1 in HNSCC patient specimen and prediction of survival of the HNSCC patients. (a) Representative pictures of triple positive (upper panel) and triple negative (lower panel) HNSCC cases. Coexpression of Bmi-1 and ALDH1 (b), Bmi-1 and Snail (c) or Snail and Bmi-1 (d) of 93 HNSCC patient samples were examined immunohistochemically. (e) Kaplan-Meier analysis of overall survival of HNSCC patients according to expression of ALDH1 (+) Bmi-1 (+) Snail (+), ALDH1 (+) Bmi-1 (+) Snail (−), ALDH1 (−) Bmi-1 (+) Snail (+) or ALDH1 (−) Bmi-1 (−) Snail (−). (*, P < .05; **, P < .01; ***, P < .001).